Abstract
Functional loss of PREX2 function sensitizes to MAPK inhibition in vitro and in vivo. A, Left, Kaplan–Meier overall survival of mice with the indicated genotypes and treatments. BRAF PTEN + vehicle (n = 8; median survival, 12.5 days) vs. BRAF PTEN + AZD6244 (n = 8; median survival, 74.5 days), P = 0.0096; BRAF PTEN PREX2 + vehicle, (n = 7; median survival, 13 days) vs. BRAF PTEN PREX2 + AZD6244 (n = 8; median survival, 108.5 days), P = 0.00005; BRAF PTEN + AZD6244 (n = 8; median survival, 74.5 days) vs. BRAF PTEN PREX2 + AZD6244 (n = 8; median survival, 108.5 days), P = 0.0021 log-rank (Mantel–Cox) test. Middle, longitudinal growth of individual tumors from vehicle-treated (n = 8) vs. AZD6244-treated (n = 7) BRAF PTEN cohorts and vehicle-treated (n = 7) vs. AZD6244-treated (n = 8) BRAF PTEN PREX2 cohorts. Right, relative change in tumor volume in mice with the indicated genotypes over the first 7 days of indicated treatment. BRAF PTEN + vehicle (n = 8), BRAF PTEN + AZD6244 (n = 7), BRAF PTEN PREX2 + vehicle (n = 7), BRAF PTEN PREX2 + AZD6244 (n = 8). P values were calculated by one-way ANOVA corrected for multiple comparisons (Tukey). B, Left, Kaplan–Meier overall survival of mice with the indicated genotypes and treatments. BRAF P53 + vehicle (n = 7; median survival, 14 days) vs. BRAF P53 + AZD6244 (n = 9; median survival, 26 days), P = 0.0204; BRAF P53 PREX2 + vehicle (n = 5; median survival, 14 days) vs. BRAF P53 PREX2 + AZD6244 (n = 8; median survival, 39 days), P = 0.0010; BRAF P53 + AZD6244 (n = 8; median survival, 14.5 days) vs. BRAF P53 PREX2 + AZD6244 (n = 10; median survival, 35 days), P = 0.0034. P values calculated using the log-rank (Mantel–Cox) test. Middle, longitudinal growth of individual tumors from vehicle-treated (n = 5) vs. AZD6244-treated (n = 4) BRAF P53 cohorts and vehicle-treated (n = 7) vs. AZD6244-treated (n = 6) BRAF P53 PREX2 cohorts. Right, relative change in tumor volume over the first 7 days of indicated treatment. BRAF P53 + vehicle (n = 5), BRAF P53 + AZD6244 (n = 4), BRAF P53 PREX2 + vehicle (n = 5), BRAF P53 PREX2 + AZD6244 (n = 6); P values, one-way ANOVA corrected for multiple comparisons (Tukey). C, Left, Kaplan–Meier overall survival of BRAF PTEN and BRAF PTEN PREX2-GD cohorts treated with vehicle or AZD6244. BRAF PTEN + vehicle (n = 8; median survival, 12.5 days) vs. BRAF PTEN + AZD6244 (n = 8; median survival, 74.5 days), P = 0.0096; BRAF PTEN PREX2-GD + vehicle (n = 6; median survival, 11 days) vs. BRAF PTEN PREX2-GD + AZD6244 (n = 8; median survival, 100.5 days), P = 0.0002; BRAF PTEN + AZD6244 (n = 8; median survival, 74.5 days) vs. BRAF PTEN PREX2-GD+AZD6244 (n = 8; median survival, 100.5 days), P = 0.0414. P values calculated using the log-rank (Mantel–Cox) test. Middle, longitudinal growth of individual tumors from vehicle-treated (n = 8) vs. AZD6244-treated (n = 7) BRAF PTEN cohorts and vehicle-treated (n = 6) vs. AZD6244-treated (n = 8) BRAF PTEN PREX2-GD cohorts. Right, relative change in tumor volume over the first 7 days of indicated treatment. BRAF PTEN + vehicle (n = 8), BRAF PTEN + AZD6244 (n = 7), BRAF PTEN PREX2-GD + vehicle (n = 5), BRAF PTEN PREX2-GD + AZD6244 (n = 6). P values calculated by one-way ANOVA corrected for multiple comparisons (Tukey). Note that the same BRAF PTEN treatment datasets are represented in A and C. D, Top left, relative confluence of parental WM266.4 cells treated with indicated treatments over the 96-hour period. Representative of a minimum of three independent experiments and three technical replicates. Data, mean ± SEM (confluence relative to starting point). Top right, relative confluence of WM266.4 PREX2KO pooled lines D2 and A4 treated with indicated treatments over the 96-hour period. Representative of a minimum of four independent experiments and three technical replicates. Data, mean ± SEM (confluence relative to starting point). Bottom left, relative confluence of WM266.4 PREX1KO pooled lines B4 and A4 treated with indicated treatments over the 96-hour period. Representative of a minimum of three independent experiments and three technical replicates. Data, mean ± SEM (confluence relative to starting point). Bottom right, relative suppression of growth, difference in calculated AUC of DMSO treated vs. AZD6244-treated lines as indicated. Center line, mean. P values calculated by one-way ANOVA corrected for multiple comparisons (Tukey).